SQZ Biotechnologies Co. (SQZ): Price and Financial Metrics


SQZ Biotechnologies Co. (SQZ): $0.57

0.01 (+1.66%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SQZ to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SQZ Stock Summary

  • SQZ has a higher market value than only 7.5% of US stocks; more precisely, its current market capitalization is $17,812,640.
  • With a year-over-year growth in debt of -60.58%, SQZ BIOTECHNOLOGIES CO's debt growth rate surpasses merely 3.86% of about US stocks.
  • In terms of volatility of its share price, SQZ is more volatile than 94.29% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to SQZ BIOTECHNOLOGIES CO, a group of peers worth examining would be DARE, INFI, SLDB, AMAM, and IPSC.
  • Visit SQZ's SEC page to see the company's official filings. To visit the company's web site, go to www.sqzbiotech.com.

SQZ Valuation Summary

  • In comparison to the median Healthcare stock, SQZ's price/sales ratio is 82.98% lower, now standing at 0.8.
  • SQZ's price/sales ratio has moved down 13.1 over the prior 29 months.

Below are key valuation metrics over time for SQZ.

Stock Date P/S P/B P/E EV/EBIT
SQZ 2023-03-24 0.8 0.3 -0.2 0.3
SQZ 2023-03-23 1.1 0.4 -0.3 0.2
SQZ 2023-03-22 0.8 0.3 -0.2 0.3
SQZ 2023-03-21 0.8 0.3 -0.2 0.1
SQZ 2023-03-20 0.7 0.2 -0.2 0.1
SQZ 2023-03-17 0.7 0.2 -0.2 0.1

SQZ's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SQZ has a Quality Grade of C, ranking ahead of 53% of graded US stocks.
  • SQZ's asset turnover comes in at 0.082 -- ranking 279th of 680 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows SQZ's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.082 1 -1.099

SQZ Price Target

For more insight on analysts targets of SQZ, see our SQZ price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $37.67 Average Broker Recommendation 1.2 (Strong Buy)

SQZ Stock Price Chart Interactive Chart >

Price chart for SQZ

SQZ Price/Volume Stats

Current price $0.57 52-week high $5.20
Prev. close $0.56 52-week low $0.53
Day low $0.56 Volume 72,800
Day high $0.59 Avg. volume 368,600
50-day MA $0.73 Dividend yield N/A
200-day MA $2.07 Market Cap 16.82M

SQZ Biotechnologies Co. (SQZ) Company Bio


SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. It operates through SQZ Cell Therapy Platform, which uses membrane disruption to deliver material into cells. The company was founded by Robert S. Langer Jr., Klavis F. Jensen, Agustin Lopez Marquez, and Armon Sharei in March 2013 and is headquartered in Watertown, MA.


SQZ Latest News Stream


Event/Time News Detail
Loading, please wait...

SQZ Latest Social Stream


Loading social stream, please wait...

View Full SQZ Social Stream

Latest SQZ News From Around the Web

Below are the latest news stories about SQZ BIOTECHNOLOGIES CO that investors may wish to consider to help them evaluate SQZ as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Thursday morning!

William White on InvestorPlace | March 23, 2023

SQZ Biotech's Cancer Candidate Shows Response At Low Dose In HPV16+ Solid Tumor Patient

SQZ Biotechnologies Company (NYSE: SQZ) announced that a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 trial. The second and third patients have also been enrolled in the trial. The company has completed the dose-limiting toxicity period for the lowest-dose cohort. The Study Safety Committee has completed its review and recommends that the company enroll patients in the highest dose cohort. The company anticipates initial c

Yahoo | March 23, 2023

SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial

WATERTOWN, Mass., March 22, 2023--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today announced that, according to RECIST 1.1 criteria, a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial. The company has decided to continue to enroll patients in the SQZ-AAC-HPV-101 clinical trial. The second and third patients have also been enrolled in the trial. The company

Yahoo | March 22, 2023

SQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio Updates

WATERTOWN, Mass., March 22, 2023--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today reported full year 2022 financial results and recent portfolio updates.

Yahoo | March 22, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

The biggest pre-market stock movers for Friday are ready to go as we dive into the latest news for investors this morning!

William White on InvestorPlace | March 17, 2023

Read More 'SQZ' Stories Here

SQZ Price Returns

1-mo -27.85%
3-mo -22.97%
6-mo -75.00%
1-year -88.15%
3-year N/A
5-year N/A
YTD -22.97%
2022 -91.71%
2021 -69.19%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8397 seconds.